News
A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.
In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...
Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.
What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the Centers for Disease Control ...
21h
Zacks Investment Research on MSNVKTX Initiates Phase 3 Study on Obesity Candidate VK2735Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results